AccidentalExpression

Full Disclaimer: AccidentalExpression is Connecting People - Learn & Share, Not Financial Advise at all. Only for entertainment purpose. Please do your own DD.

[BRexNew @BRexNew]

$200+ You all know/understand what’s going on. RIGHT!

The FDA BP HedgeF entities that have their foot on the neck of #Ocugen

#OCU400 P2/3 significant evidence of effectiveness
#OCU410 P2 as above
#OCU410ST P2/3 as above

It’s not risk, it’s nefarious corrupt entities!!
$OCGN

[TheUrbanFarmer @NattaCop]

$OCGN Hello fam, I want to show you a real example of what happens when biotech speculation turns into reality.

The chart below is Celcuity, ticker CELC, over a little more than a year. CELC is a strong comparison to Ocugen in terms of market setup.

Pre revenue biotech + ignored asset + Phase 3 derisking event + regulatory filing path + huge commercial story = violent rerate.

CELC had its major move after the VIKTORIA 1 Phase 3 trial showed gedatolisib produced a 76% reduction in risk of progression or death in the triplet arm and a 67% reduction in the doublet arm versus fulvestrant. After that, the story moved from clinical speculation into NDA submission and FDA review territory.

That is what the market does in biotech.

It waits.
It doubts.
It discounts.
It suppresses.

Then pivotal data hits, the filing path becomes real, and the entire valuation framework changes almost overnight.

CELC went from being valued like a risky clinical biotech to being valued like a near commercial oncology company once the data proved the drug worked.

Ocugen will go from being valued like a beaten down speculative microcap to being valued like a near commercial gene therapy platform as soon as OCU400 data proves the drug works.

There is one exception though, and it is pretty massive.

Ocugen has something CELC does not have in the same way: platform stacking.

CELC is largely a gedatolisib story.

Ocugen has OCU400 as the first major validation point, then OCU410ST behind it, then OCU410 for GA, which both have already shown statistical superiority.

OCU400’s pivotal win won’t just cause the market to price in the one drug. It would force the market to reprice the entire modifier gene therapy platform.

One product moves toward approval.
The platform gets validated.
The follow on programs become impossible to discount.
Our commercial story becomes reality.

🍻 🐂

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN ... #Oppenheimer is
single investment entity in this transaction....

https://t.co/uyA0f6tXbO

[AccidentalExpression @BlogToWorld]

💯💯💯💯💯

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN

Retail investors get scared and sell, institutional investors are buying it out right under us. Get smart guys!

OCGN - Ocugen, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM) https://t.co/yvYixZHFGb

[AccidentalExpression @BlogToWorld]

😇🙏

[TheUrbanFarmer @NattaCop]

$OCGN Institutional ownership is rising fast, and this is before the 2026 Russell reconstitution cycle even hits.

Russell finalizes after market close June 26, with the newly reconstituted indexes live June 29.

Ocugen has the cash now, and they’re have 3 BLA filings over the next 2 years.

Where this stock is going is obvious to me. The whole reason I’m here is to bring retail awareness to what I believe will become the next big pharma before the market recognizes the value.

Good news, and lots of it, comes next. When this starts getting crazy, it won’t move in a nice straight line. We’ll stair step up. There will be stop loss raids after jumps, emotional decisions, and regret.

If you’ve been here with me on this journey, remember the big picture.

Know what you own. Have a plan in place. Let that plan dictate future decisions, not volatility, fear, or big money shake outs and stop losses.

We’re approaching the moment where speculation meets reality.

Js 🍻

[Ocugen @Ocugen]

Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.

Learn more: https://t.co/7nSj5EJkPZ

#GeneTherapy #Biotech #FinancialUpdate $OCGN

[BRexNew @BRexNew]

You all are living in cloud cookoo land if you’re believing these BULL💩 analysts price targets FFS.

We’ve come a VERY long way since 2017/19, it’s 2026!

#OCU400 #OCU410 #OCU410ST treats 100’s to 2m+ patients worldwide.

Worth $10 don’t make me 🤣🤣

It’s $100+

$OCGN #Ocugen

[BRexNew @BRexNew]

Did you actually listen to the CEO.

The note will/can be repaid in CASH, commercial revenues, partnerships etc.

Therefore, high possibility that there could be no dilution at all.

We’re talking $M/B’s in incoming revenues.

What’s $100m to 3 IRD treatments $$$

$OCGN #OCU400

[Billythekid123 @B1llyTh2K3d]

@MoreFlax Looking to go nuclear

[Shankar Musunuri @drsmusunuri]

Encouraging to see continued progress across our pipeline and operations this quarter. With key milestones achieved and a strong balance sheet, we are well positioned as we advance toward the next phase of development and potential filings.

#GeneTherapy #Biotech

[Mr.OcugenInvestor @kickstarterx10]

$OCGN $115M convertible notes offering (up to $130M)

Here’s how I’m seeing it:

• 💰 Strategic move to secure capital ahead of commercialization
• 🧬 Strengthens balance sheet & extends runway for key programs
• 📉 Near-term pressure expected (convertible/dilution concerns)
• 🧠 Classic biotech play: fund growth before major milestones
• 🚀 Positions company to execute without rushing into unfavorable deals

Short-term noise, long-term vision. #Biotech

[AccidentalExpression @BlogToWorld]

💯

[Mr.OcugenInvestor @kickstarterx10]

$OCGN 🙏 Big thanks to Ocugen management for listening to long-term retail investors and removing the RS vote from the final proxy. That shows concerns were heard and taken seriously. 👏

💙 A special thank you to @drsmusunuri and the leadership team for understanding shareholder sentiment at such an important moment.

💪 Credit to every long-term investor who spoke up, stayed engaged, and fought to have this taken out. Good job to all of us.

🚀 Now the path looks much clearer: execution, catalysts, and what could be a huge green upside ahead. 📈🟢

$OCGN #Ocugen

[AccidentalExpression @BlogToWorld]

😇🙏

[Billythekid123 @B1llyTh2K3d]

Also for anyone who didn’t already see it or hear about it $OCGN

The reverse split proposal is officially off the table.

See ya tomorrow. 🗓️

[Billythekid123 @B1llyTh2K3d]

Also for anyone who didn’t already see it or hear about it $OCGN

The reverse split proposal is officially off the table.

See ya tomorrow. 🗓️

[Billythekid123 @B1llyTh2K3d]

@MoreFlax @Ocugen Proud of you @MoreFlax 🤙 and proud to be here next to you.

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

It is final proxy and RS is out !!!

We will have live spaces at 8pm.

Congratulations to all, @Ocugen team have listened to retail investors.

💥💥💥💥

[Billythekid123 @B1llyTh2K3d]

I used to say “I’ll never stop fighting for you”

Now I’ll say: I’ll never stop fighting alongside you. #OcuFam $OCGN

To the end. 🤙

[Billythekid123 @B1llyTh2K3d]

Last thing I’ll post for a while. (Probably see ya on the 29th) $OCGN

[Billythekid123 @B1llyTh2K3d]

Why am I pushing for the OS increase? $OCGN

Because a reverse split is a double-whammy of dilution.

If we increase the OS, your personal share count remains the same and the Co. has more room.

If they RS, your position is immediately diluted with room for further dilution.